27. THE USE OF COMBINATION THERAPY IN THE TREATMENT OF HEART FAILURE IN PATIENTS WITH REDUCED EJECTION FRACTION ACCORDING TO ESC 2021 GUIDELINES
Main Article Content
Abstract
Background: The treatment of heart failure with reduced ejection fraction in Vietnam is of great concern, not only reflected in the increased incidence and prevalence but also in the issue of using drug combinations in treatment, this problem, however, becomes more concerning when the European Heart Association recently announced an additional group of drugs that have the ability to improve mortality prognosis in patients with heart failure with reduced ejection fraction [1]. The study conducted a survey on the combination of all four drugs in the treatment of heart failure with reduced ejection fraction at Thong Nhat Hospital from July 2023 to April 2024
Objective: Determine the proportion of heart failure patients with reduced EF who are using all medication groups as recommended by the 2021 European Society of Cardiology guidelines.
Methods: Our cross-sectional study was conducted on 87 patients with stable heart failure and reduced EF currently being treated at the cardiology department and clinic of Thong Nhat Hospital from July 2023 to April 2024.
Results: The proportion of heart failure patients with reduced EF who are treated with all four medication groups is 40.2%. The main reasons include patients having relative contraindications to the medication groups, patient adherence, and economic issues.
Conclusion: The rate of non-adherence among patients is high, thus it is necessary to develop health education communication programs, implement measures to encourage people to participate in health insurance, and increase the use of full treatment once contraindications are resolved.
Article Details
Keywords
ESC 2021, heart failure with reduced ejection fraction, Thong Nhat hospital
References
[2] Dokainish, H., et al (2017). Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet Global Health, 2017. 5(7): p. e665-e672.
[3] 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032. doi: 10.1161/CIR.0000000000001063
[4] Hướng dẫn điều trị suy tim cấp và mạn, Bộ Y tế, 2022.
[5] Phan Đình Phong, Phạm Thị Mai Hương, Đặng Việt Phong, et al (2024). Thực trạng sử dụng các nhóm thuốc nền tảng trong điều trị suy tim mạn tính có phân suất tống máu giảm tại Khoa khám bệnh - Bệnh viện Bạch Mai. Tạp chí y học Việt Nam 2024, tập 535.
[6] Thái Trường Nhã, Trần Trọng Quốc Trưởng, Điêu Thanh Hùng (2023). Khảo sát sử dụng thuốc trong điều trị suy tim phân suất tống máu giảm tại Bệnh viện Tim mạch An Giang.
[7] Trần Đại Cường, Phạm Dương Lành, Hoàng Văn Sỹ (2024). Khảo sát điều trị suy tim theo khuyến cáo của hội tim châu âu 2021 ở các mức phân suất tống máu khác nhau. Tạp chí y học Việt Nam 2024, tập 534.